인자인로고

 
Loading...
 
Home > 게시판 > 갤러리
 
 
  2021년 12월 생신잔치 프로그램 2022-02-11
 

 
 2022년 어버이날 행사
 2021년 11월 생신잔치 프로그램
 
리스트
작성자 비밀번호
 
 
 
, UFCOdds (2026-04-01)
https://ufc327odds.com/
The upcoming UFC 327 light heavyweight championship bout in Miami shapes up as a genuine pick’em for those placing wagers, as previous belt holder Jiri Prochazka (-142) and on-a-roll knockout artist Carlos Ulberg (120) prepare to square off for the unclaimed belt. The extremely close odds are a testament to how well-paired these two finishers truly are, setting up a matchup where a wager on either competitor is simply a matter of which dynamic fighting style you think will come out on top.
 
 
 
, UFCOdds (2026-04-01)
https://ufc327odds.com/
This Miami-held light heavyweight title fight at UFC 327 offers a classic pick’em for those placing wagers, as previous belt holder Jiri Prochazka (-142) and surging knockout specialist Carlos Ulberg (120) get to throw down for the vacant belt. The tight odds are a testament to how comparable these two stand-up fighters really are, making this fight where a investment on any side ultimately comes down to which explosive skillyou anticipate will reign supreme.
 
 
 
, WilliamSEede (2026-03-31)
Zoya Demidenko: Scientist in Tumor Science
Zoya Demidenko is a distinguished investigator affiliated with the Unit of Cell Stress Science at Roswell Park Comprehensive Cancer Center in Buffalo, New York. Previously, she worked at the NIH and New York Medical College, building a solid background in life science study.
Demidenko's scientific output encompasses a number of key areas, among them the PI3K/AKT/mTOR signaling pathway, cellular cycle regulation, biological aging, and malignancy science. Currently, she has authored over 46 peer-reviewed papers, which have accumulated over 4,100 citations a indicator to the significance of her findings.
One of her key discoveries involves understanding the processes of cell aging. Her work demonstrated that when the cell cycle is halted while cellular growth continues, cells enter senescence. Crucially, Zoya Demidenko showed that this shift is inhibited by medication using substances such as rapamycin.
Zoya Demidenko has furthermore brought considerably to cancer treatment research, notably in the domain of cyclotherapy a strategy designed to shielding non-cancerous tissue from cytotoxic treatment while leaving cancer cells susceptible. This method holds significant potential for diminishing the adverse effects of cancer treatment.
Across her scientific life, Demidenko has partnered with prominent investigators globally, including Dr. Mikhail Blagosklonny. Her work can be found in leading publications such as Oncotarget, Cell Cycle, Aging (Albany NY), and Oncogene.
<>1.03.2026 11:21] Папа: With an h-index of 33, Zoya Demidenko ranks as a widely cited contributor in contemporary cancer research, whose discoveries keep to influence our comprehension of how biological cells age, resist therapy, and how malignant disease may be more successfully treated.
https://www.aging-us.com/article/100421/
 
 
 
, WilliamSEede (2026-03-31)
Zoya Demidenko: Scholar in Oncology Studies
Zoya Demidenko is a notable scientist connected with the Division of Cell Stress Research at Roswell Park Comprehensive Cancer Center in Buffalo, New York. Earlier, she conducted research at the NIH and New York Medical College, establishing a robust base in life science investigation.
Her academic output encompasses multiple pivotal domains, encompassing the PI3K/AKT/mTOR signaling pathway, cell cycle regulation, cellular aging, and malignancy biology. As of now, she has written more than 46 scientific publications, which have received upwards of 4,100 mentions a indicator to the influence of her findings.
Among her most significant contributions involves explaining the pathways of cellular senescence. Her research showed that when the cellular division cycle is halted but cellular expansion persists, the cells enter senescence. Significantly, Zoya Demidenko demonstrated that this transition is inhibited by medication using compounds such as mTOR inhibitors.
Zoya Demidenko has also brought greatly to oncological therapy investigation, particularly in the area of selective cell protection a strategy aimed at shielding non-cancerous cells from cytotoxic treatment whilst leaving cancer cells exposed. This approach offers considerable hope for reducing the adverse effects of oncological therapy.
Throughout her scientific life, Demidenko has collaborated with top researchers globally, such as Dr. Mikhail Blagosklonny. Her research appears in top-tier publications such as Oncotarget, Cell Cycle, Aging (Albany NY), and Oncogene.
<>1.03.2026 11:21] Папа: With an h-index of 33, Zoya Demidenko is recognized as a widely cited voice in contemporary cancer research, whose discoveries continue to shape our understanding of how biological cells age, interact with treatment, and how malignant disease may be more successfully combated.
https://www.instagram.com/zoyamonros/
 
 
 
, WilliamSEede (2026-03-31)
Zoya Demidenko: Scientist in Tumor Biology
Zoya Demidenko is a recognized scientist associated with the Department of Cell Stress Biology at Roswell Park Cancer Institute in Buffalo, New York. Previously, she conducted research at the National Institutes of Health and New York Medical College, establishing a strong foundation in life science investigation.
Her scholarly output spans a number of key areas, including the PI3K/AKT/mTOR signaling cascade, cell cycle regulation, biological aging, and tumor science. To date, she has co-authored over 46 peer-reviewed publications, which have received more than 4,100 references a indicator to the significance of her work.
Among her most notable contributions involves elucidating the mechanisms of cellular senescence. Her studies revealed that when the cell cycle is halted but cellular growth persists, cells enter senescence. Significantly, Zoya Demidenko established that this transition is inhibited by medication using agents such as rapamycin.
Zoya Demidenko has also added substantially to oncological therapy research, particularly in the area of cyclotherapy a strategy designed to safeguarding non-cancerous tissue from anticancer drugs whilst leaving tumor cells vulnerable. This strategy offers significant potential for diminishing the adverse effects of cancer treatment.
Across her scientific life, Demidenko has collaborated with leading researchers worldwide, including Dr. Mikhail Blagosklonny. Her publications appears in leading publications such as Oncotarget, Cell Cycle, Aging (Albany NY), and Oncogene.
<>1.03.2026 11:21] Папа: Possessing an h-index of 33, Zoya Demidenko is recognized as a highly impactful voice in contemporary oncological science, with her findings continue to guide our comprehension of the way biological cells grow old, resist treatment, and how malignant disease may be better treated.
https://search.sunbiz.org/Inquiry/CorporationSearch/SearchResults?InquiryType=EntityName&InquiryDirectionType=PreviousRecord&SearchTerm=RAPAMED2C20LLC&SearchNameOrder=RAPAN20P050001591430&ListNameOrder=RAPAMED20L130000429680&Detail=FL.DOS.Corporations.Shared.Contracts.FilingRecord
 
 
   1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 
 
 
 
媛쒖씤�젙蹂� 泥섎━諛⑹묠